Aeterna Zentaris Inc.
AEZS
Price:
$5.72
Market Cap:
$17.51M
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercializ...[Read more]
Industry
Biotechnology
IPO Date
2000-05-10
Stock Exchange
NASDAQ
Ticker
AEZS
PE Ratio
[-2.48]
ROE
[-84.15%]
Current Ratio
[5.94]
Dividend Yield
[0%]
Enterprise Value
[-11767918.00]
Dividend History
The ROE as of December 2024 (TTM) for Aeterna Zentaris Inc. (AEZS) is -84.15%
According to Aeterna Zentaris Inc.’s latest financial reports and current stock price. The company's current ROE is -84.15%. This represents a change of 234.54% compared to the average of -25.15% of the last 4 quarters.
Aeterna Zentaris Inc. (AEZS) Historical ROE (quarterly & annually)
How has AEZS ROE performed in the past?
The mean historical ROE of Aeterna Zentaris Inc. over the last ten years is 6.73%. The current -84.15% ROE has changed -1349.87% with respect to the historical average. Over the past ten years (40 quarters), AEZS's ROE was at its highest in in the September 2017 quarter at 492.63%. The ROE was at its lowest in in the June 2020 quarter at -370.57%.
Average
6.73%
Median
-65.93%
Minimum
-401.79%
Maximum
603.52%
Aeterna Zentaris Inc. (AEZS) ROE by Quarter and Year
Discovering the peaks and valleys of Aeterna Zentaris Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 566.70%
Maximum Annual ROE = 603.52%
Minimum Annual Increase = -386.35%
Minimum Annual ROE = -401.79%
| Year | ROE | Change |
|---|---|---|
| 2023 | -93.11% | -11.57% |
| 2022 | -105.29% | 566.70% |
| 2021 | -15.79% | -59.23% |
| 2020 | -38.74% | -115.79% |
| 2019 | 245.31% | 11.73% |
| 2018 | 219.56% | -63.62% |
| 2017 | 603.52% | -250.21% |
| 2016 | -401.79% | 73.20% |
| 2015 | -231.98% | 102.85% |
| 2014 | -114.36% | -386.35% |
Aeterna Zentaris Inc. (AEZS) Average ROE
How has AEZS ROE performed in the past?
The current ROE of Aeterna Zentaris Inc. (AEZS) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-71.40%
5-year avg
-1.52%
10-year avg
6.73%
Aeterna Zentaris Inc. (AEZS) ROE vs. Peers
How is AEZS’s ROE compared to its peers?
Aeterna Zentaris Inc.’s ROE is greater than Pulmatrix, Inc. (-63.07%), less than Onconova Therapeutics, Inc. (619.75%), greater than Catalyst Biosciences, Inc. (-63.14%), less than Bio-Path Holdings, Inc. (2.62%), greater than Moleculin Biotech, Inc. (-165.56%), greater than Adial Pharmaceuticals, Inc. (-256.25%), greater than Diffusion Pharmaceuticals Inc. (-44.12%), greater than Tonix Pharmaceuticals Holding Corp. (-163.95%), less than Jaguar Health, Inc. (0%), greater than Acasti Pharma Inc. (-287.85%), greater than iBio, Inc. (-18.84%), greater than TransCode Therapeutics, Inc. (-126.61%), greater than Aditxt, Inc. (-649.01%), greater than Reviva Pharmaceuticals Holdings, Inc. (-431.38%), less than Avenue Therapeutics, Inc. (1.15%), greater than null (-473.61%),
| Company | ROE | Market cap |
|---|---|---|
| -63.07% | $21.53M | |
| 619.75% | $20.90M | |
| -63.14% | $19.42M | |
| 2.62% | $4.61M | |
| -165.56% | $5.44M | |
| -256.25% | $6.60M | |
| -44.12% | $8.98M | |
| -163.95% | $73.34M | |
| 0% | $11.54M | |
| -287.85% | $34.17M | |
| -18.84% | $22.05M | |
| -126.61% | $2.35M | |
| -649.01% | $2.73M | |
| -431.38% | $81.28M | |
| 1.15% | $3.63M | |
| -473.61% | $0 |
Build a custom stock screener for Aeterna Zentaris Inc. (AEZS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aeterna Zentaris Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Aeterna Zentaris Inc. (AEZS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Aeterna Zentaris Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Aeterna Zentaris Inc.'s ROE?
How is the ROE calculated for Aeterna Zentaris Inc. (AEZS)?
What is the highest ROE for Aeterna Zentaris Inc. (AEZS)?
What is the 3-year average ROE for Aeterna Zentaris Inc. (AEZS)?
What is the 5-year average ROE for Aeterna Zentaris Inc. (AEZS)?
How does the current ROE for Aeterna Zentaris Inc. (AEZS) compare to its historical average?